Literature DB >> 17063391

Effect of electroconvulsive shock on mitochondrial respiratory chain in rat brain.

Márcio Búrigo1, Clarissa A Roza, Cintia Bassani, Diego A Fagundes, Gislaine T Rezin, Gustavo Feier, Felipe Dal-Pizzol, João Quevedo, Emilio L Streck.   

Abstract

It is well described that impairment of energy production has been implicated in the pathogenesis of a number of diseases. Although several advances have occurred over the past 20 years concerning the use and administration of electroconvulsive therapy (ECT) to minimize its side effects, little progress has been made in understanding its mechanism of action. In this work, our aim was to measure the activities of mitochondrial respiratory chain complexes II and IV and succinate dehydrogenase from rat brain after acute and chronic electroconvulsive shock (ECS). Our results showed that mitochondrial respiratory chain enzymes activities were increased after acute ECS in hippocampus, striatum and cortex of rats. Besides, we also demonstrated that complex II activity was increased after chronic ECS in cortex, while hippocampus and striatum were not affected. Succinate dehydrogenase, however, was inhibited after chronic ECS in striatum, activated in cortex and not affected in hippocampus. Finally, complex IV was not affected by chronic ECS in hippocampus, striatum and cortex. Our findings demonstrated that brain metabolism is altered by ECS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17063391     DOI: 10.1007/s11064-006-9185-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  21 in total

Review 1.  Neurochemical mechanisms of action of ECS: evidence from in vivo studies.

Authors:  M E Newman; E Gur; B Shapira; B Lerer
Journal:  J ECT       Date:  1998-09       Impact factor: 3.635

2.  Regional mitochondrial respiratory activity in Huntington's disease brain.

Authors:  W A Brennan; E D Bird; J R Aprille
Journal:  J Neurochem       Date:  1985-06       Impact factor: 5.372

3.  Blood glucose before and after ECT treatments in Type 2 diabetic patients.

Authors:  Keith G Rasmussen; Debra A Ryan; Paul S Mueller
Journal:  J ECT       Date:  2006-06       Impact factor: 3.635

Review 4.  Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia?

Authors:  J P Blass
Journal:  J Neurosci Res       Date:  2001-12-01       Impact factor: 4.164

5.  Ketamine and phenobarbital do not reduce the evoked-potential enhancement induced by electroconvulsive shock seizures in the rat.

Authors:  Z Gombos; A Mendonça; G A Cottrell; W M Burnham
Journal:  Neurosci Lett       Date:  1999-11-05       Impact factor: 3.046

6.  Differential investigation of the capacity of succinate oxidation in human skeletal muscle.

Authors:  J C Fischer; W Ruitenbeek; J A Berden; J M Trijbels; J H Veerkamp; A M Stadhouders; R C Sengers; A J Janssen
Journal:  Clin Chim Acta       Date:  1985-11-29       Impact factor: 3.786

7.  Increased neurogenesis in a model of electroconvulsive therapy.

Authors:  T M Madsen; A Treschow; J Bengzon; T G Bolwig; O Lindvall; A Tingström
Journal:  Biol Psychiatry       Date:  2000-06-15       Impact factor: 13.382

8.  Structure-related oxidative damage in rat brain after acute and chronic electroshock.

Authors:  T Barichello; F Bonatto; F R Agostinho; A Reinke; J C F Moreira; F Dal-Pizzol; I Izquierdo; J Quevedo
Journal:  Neurochem Res       Date:  2004-09       Impact factor: 3.996

9.  Regional cerebral blood flow in mood disorders, III. Treatment and clinical response.

Authors:  M S Nobler; H A Sackeim; I Prohovnik; J R Moeller; S Mukherjee; D B Schnur; J Prudic; D P Devanand
Journal:  Arch Gen Psychiatry       Date:  1994-11

Review 10.  Does ECT alter brain structure?

Authors:  D P Devanand; A J Dwork; E R Hutchinson; T G Bolwig; H A Sackeim
Journal:  Am J Psychiatry       Date:  1994-07       Impact factor: 18.112

View more
  4 in total

Review 1.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 2.  Mitochondrial dysfunction and psychiatric disorders.

Authors:  Gislaine T Rezin; Graziela Amboni; Alexandra I Zugno; João Quevedo; Emilio L Streck
Journal:  Neurochem Res       Date:  2008-11-01       Impact factor: 3.996

3.  Nucleus accumbens deep-brain stimulation efficacy in ACTH-pretreated rats: alterations in mitochondrial function relate to antidepressant-like effects.

Authors:  Y Kim; S McGee; J K Czeczor; A J Walker; R P Kale; A Z Kouzani; K Walder; M Berk; S J Tye
Journal:  Transl Psychiatry       Date:  2016-06-21       Impact factor: 6.222

Review 4.  An investigation into closed-loop treatment of neurological disorders based on sensing mitochondrial dysfunction.

Authors:  Scott D Adams; Abbas Z Kouzani; Susannah J Tye; Kevin E Bennet; Michael Berk
Journal:  J Neuroeng Rehabil       Date:  2018-02-13       Impact factor: 4.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.